Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 9636388 Multi-indication mRNA cancer immunotherapy

Patent 9636388 was granted and assigned to Morphogenesis, Inc. on May, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

Currently, there are no issues on this topic.

Find more entities like US Patent 9636388 Multi-indication mRNA cancer immunotherapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo